Once-Weekly Oral HIV Treatment Regimen Demonstrates Efficacy in Phase 3 Trials

Merck and Gilead Sciences have announced positive detailed outcomes from Phase 3 trials for an investigational once-weekly oral HIV treatment. The regimen, combining islatravir and lenacapavir, successfully maintained viral suppression in adults who transitioned from other antiretroviral therapies. The safety profile was found to be consistent with existing treatments, and these results will support future regulatory submissions. This development could offer a significant improvement in convenience and adherence for individuals managing HIV.